✉news WorldEU Politics first seen 1 d ago, last 1 d ago, peak #6
EU Approves T-DXd for Residual HER2-Positive Early Breast Cancer
Original: T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
The European Union has approved trastuzumab deruxtecan (T-DXd) for patients with residual HER2-positive early breast cancer, expanding access to the antibody-drug conjugate beyond its existing metastatic indications. The decision follows positive trial results showing improved outcomes for patients with remaining disease after neoadjuvant therapy. Oncologists have welcomed the approval as a meaningful new treatment option in the curative-intent setting.
Why now: The EU's regulatory approval of a major oncology drug in a new early-stage setting is fresh news of direct relevance to cancer patients and clinicians.
T-DXdEuropean UnionDaiichi SankyoAstraZenecaHER2-positive breast cancer
Rank over time, top of the chart is #1. 9 snapshots from 1 d ago to 1 d ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/3875906